相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis
Chinthaka B. Samaranayake et al.
INTERNAL MEDICINE JOURNAL (2022)
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism A Randomized Trial
Benjamin Planquette et al.
CHEST (2022)
Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis
Shujie Dong et al.
ANNALS OF PHARMACOTHERAPY (2021)
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study
Walter Ageno et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis
Mostafa El Mokadem et al.
VASCULAR (2021)
Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs)
Xiaojun Song et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis
V Mai et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non-Vitamin K Antagonists Oral Anticoagulants
Panteleimon E. Papakonstantinou et al.
CURRENT PHARMACEUTICAL DESIGN (2020)
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients: a systematic review and network meta-analysis
Zechang Xin et al.
ANNALS OF PALLIATIVE MEDICINE (2020)
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm A Randomized Clinical Trial
Saketh R. Guntupalli et al.
JAMA NETWORK OPEN (2020)
Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials
Florian Moik et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis
Ang Li et al.
THROMBOSIS RESEARCH (2019)
Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients
Xiaoli Wang et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Renato D. Lopes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis
Anne Rossel et al.
PLOS ONE (2019)
Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies
Yunsong Wang et al.
FRONTIERS IN PHARMACOLOGY (2019)
How can we reverse bleeding in patients on direct oral anticoagulants?
Mark Crowther et al.
KARDIOLOGIA POLSKA (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis
Harry E. Fuentes et al.
MAYO CLINIC PROCEEDINGS (2019)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis
Maria Cristina Vedovati et al.
THROMBOSIS RESEARCH (2018)
Cancer-Associated Venous Thromboembolic Disease, Version 2.2018 Featured Updates to the NCCN Guidelines
Michael B. Streiff et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
Daniel M. Witt et al.
BLOOD ADVANCES (2018)
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Cihan Ay et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge et al.
LANCET ONCOLOGY (2016)
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE
Miriam Bach et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Gary E. Raskob et al.
LANCET HAEMATOLOGY (2016)
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial
Agnes Y. Y. Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
Gary H. Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial
G. Agnelli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer
Sam Schulman et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Gary H. Lyman et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Calvin H. Yeh et al.
BLOOD (2014)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman et al.
CIRCULATION (2014)
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials
Martin H. Prins et al.
LANCET HAEMATOLOGY (2014)
Epidemiology of cancer-associated venous thrombosis
Jasmijn F. Timp et al.
BLOOD (2013)
CANCER-ASSOCIATED THROMBOTIC DISEASE Treatment of cancer-associated thrombosis
Agnes Y. Y. Lee et al.
BLOOD (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Martin H. Prins et al.
THROMBOSIS JOURNAL (2013)
Parenteral Anticoagulants Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
David A. Garcia et al.
CHEST (2012)
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
M. N. Levine et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting The Recovery Study
Susan R. Kahn et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Epidemiology, risk factors for stroke, and management of atrial fibrillation in China
Dayi Hu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
分享论文
